Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline

RMD Open. 2020 Oct;6(3):e001323. doi: 10.1136/rmdopen-2020-001323.

Authors

Serena Bugatti^{1

2}, Ludovico De Stefano^{3

2}, Francesca Bobbio-Pallavicini³, Carlomaurizio Montecucco^{3

2}

Affiliations

¹ Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy serena.bugatti@unipv.it.
² Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
³ Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

No abstract available

Keywords: Arthritis; Hydroxychloroquine; Lupus Erythematosus; Rheumatoid; Systemic.

MeSH terms

Antirheumatic Agents / pharmacology
Antirheumatic Agents / therapeutic use*
Betacoronavirus / drug effects
COVID-19
Coronavirus Infections / prevention & control*
Humans
Hydroxychloroquine / pharmacology
Hydroxychloroquine / therapeutic use*
Pandemics / prevention & control*
Pneumonia, Viral / prevention & control*
Rheumatologists*
SARS-CoV-2

Substances

Antirheumatic Agents
Hydroxychloroquine